Empire Genomics, LLC (EG) announced that it has formed a strategic alliance with BioDiscovery, Inc (BD) to offer complete solutions to customers in the array comparative genomic hybridization field.
Empire’s aCGH services and products will be combined with BioDiscovery’s proprietary software to reduce the difficulty in obtaining quality data from assays. EG and BDI will optimize their products to ensure consistency from assay to assay and researcher to researcher.
Further EG and BDI will work to continually develop and bring new products to market. Also as a part of this alliance Empire Genomics and BioDiscovery will co-market and co-promote their products and services to end users.
“This alliance with BioDiscovery is part of our core strategy to work to bring the best solutions to our Empire customers. While we possess the best in aCGH kits and services it is crucial to have a software offering that is just as great and user friendly; in BioDiscovery we have that!,” commented Anthony Johnson, CEO of Empire Genomics.
“As we continue to bring novel technologies and diagnostic products to market, reducing variability and ensuring that our customers can consistently get desired results from their experiments are of a paramount importance to our business model. I am thoroughly pleased to work with BioDiscovery and truly excited about our future,” Johnson added.
“We are very excited about working with Empire Genomics in providing a high quality complete solution to our mutual customers. Having worked with EG array images, we know that they are of high quality and combining those with BioDiscovery’s leading image and aCGH analysis software ImaGene CGH provides a truly best-in-class solution,” said Dr. Soheil Shams, President of BioDiscovery.
“We look forward to expanding our collaboration with Empire Genomics and continuing to provide innovative software solutions for CGH research.”